NG 25 is a potent type II kinase inhibitor targeting MAP4K2, TAK1, Src/LYN, and Abl family kinases. It demonstrates anti-inflammatory effects by inhibiting TNF-α-induced NF-κB signaling and suppresses viability in KRAS-mutant colorectal cancer cells. In vivo, it reduces tumor growth in a CT26 mouse model.